Clinical and experimental dermatology · 2024
Clinical outcomes of the management of basal cell carcinomas in individuals aged 90 years and over: a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nicholls Isabelle, Moncrieff Marc, Patel Martyn, Nobes Jenny, Garioch Jennifer
Аннотация
BACKGROUND: A retrospective cohort study was undertaken to examine the management of basal cell carcinoma (BCC) in older patients.
OBJECTIVES: The aim of this study was to identify subgroups where intervention could be minimized, based on frailty and trends in survival.
METHODS: All patients aged ≥ 90 years with histologically confirmed BCC during 2017 and 2018 were included within the study (n = 319).
RESULTS: Age was the most significant predictor of survival [hazard ratio (HR) 1.10, 95% confidence interval (CI) 1.04-1.17; P = 0.001]. Maximum threshold analysis identified 93 years as the significant age cutpoint. Median survival was 40 months for patients aged ≤ 93 years and 28 months for those aged > 93 years (P = 0.002). Patients with dementia had a worse survival than those without (median survival 25 months vs. 35 months, respectively; HR 1.92, 95% CI 1.18-3.13; P = 0.009). There was a statistically significant difference in survival for patients who received treatment for their BCC (n = 294) compared with the untreated cohort (n = 25) (median survival 34 months vs. 21 months, respectively; HR 0.54, 95% CI 0.34-0.85; P = 0.007). All other comorbidities examined had no influence on survival.
CONCLUSIONS: This study provides evidence in support of active treatment of BCC in individuals aged ≥ 90 years, seen in secondary care. Conservative options may be preferable in patients with dementia or those > 93 years old.
OBJECTIVES: The aim of this study was to identify subgroups where intervention could be minimized, based on frailty and trends in survival.
METHODS: All patients aged ≥ 90 years with histologically confirmed BCC during 2017 and 2018 were included within the study (n = 319).
RESULTS: Age was the most significant predictor of survival [hazard ratio (HR) 1.10, 95% confidence interval (CI) 1.04-1.17; P = 0.001]. Maximum threshold analysis identified 93 years as the significant age cutpoint. Median survival was 40 months for patients aged ≤ 93 years and 28 months for those aged > 93 years (P = 0.002). Patients with dementia had a worse survival than those without (median survival 25 months vs. 35 months, respectively; HR 1.92, 95% CI 1.18-3.13; P = 0.009). There was a statistically significant difference in survival for patients who received treatment for their BCC (n = 294) compared with the untreated cohort (n = 25) (median survival 34 months vs. 21 months, respectively; HR 0.54, 95% CI 0.34-0.85; P = 0.007). All other comorbidities examined had no influence on survival.
CONCLUSIONS: This study provides evidence in support of active treatment of BCC in individuals aged ≥ 90 years, seen in secondary care. Conservative options may be preferable in patients with dementia or those > 93 years old.